伴有异常CD16和CD56自然杀伤细胞标志物表达的急性髓系白血病的不良预后。

Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression.

作者信息

Junge Alexandra, Bacher Ulrike, Mueller Beatrice U, Keller Peter, Solenthaler Max, Pabst Thomas

机构信息

Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Switzerland.

Department of Hematology, Inselspital, University Hospital Bern, University of Bern, Switzerland.

出版信息

Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2516.

DOI:10.1002/hon.2516

PMID:29862539

Abstract

Natural killer cells mediate antibody-dependent cell-mediated cytotoxicity, and CD16 exerts key functions to induce antibody-dependent cell-mediated cytotoxicity response. Because the prognostic relevance of aberrant CD16 expression in AML patients at diagnosis is unknown, we analyzed 325 AML patients undergoing intensive chemotherapy for aberrant CD16+ and CD56+ natural killer-cell marker expression. CD56+ AML patients had inferior median event-free (EFS; P = 0.0699) and overall survival (OS; 10.9 versus 20.6 months; P = 0.0132). Patients expressing CD16 had worse median EFS (P = 0.0622) and OS (13.0 versus 45.9 months; P = 0.0277). EFS for CD16+/CD56+ patients was 5.7 months compared with 7.1 months for CD16-/CD56- (P = 0.3690), and OS was 10.6 months for CD16+/CD56+ patients compared with 52.2 months for CD16-/CD56- patients (P = 0.0311). Patients with CD16+/CD56+ expression had a lower probability to achieve complete remission after 2 induction cycles (52% versus 72%). Our data suggest that AML patients with aberrant CD16 and CD56 expression have adverse survival outcomes.

摘要

自然杀伤细胞介导抗体依赖的细胞介导的细胞毒性作用，而CD16在诱导抗体依赖的细胞介导的细胞毒性反应中发挥关键作用。由于初诊时急性髓系白血病（AML）患者中异常CD16表达的预后相关性尚不清楚，我们分析了325例接受强化化疗的AML患者异常CD16 +和CD56 +自然杀伤细胞标志物的表达情况。CD56 + AML患者的无事件生存期（EFS）中位数较差（P = 0.0699），总生存期（OS）也较差（10.9个月对20.6个月；P = 0.0132）。表达CD16的患者EFS中位数更差（P = 0.0622），OS也更差（13.0个月对45.9个月；P = 0.0277）。CD16 + / CD56 +患者的EFS为5.7个月，而CD16 - / CD56 - 患者为7.1个月（P = 0.3690），CD16 + / CD56 +患者的OS为10.6个月，而CD16 - / CD56 - 患者为52.2个月（P = 0.0311）。CD16 + / CD56 +表达的患者在2个诱导周期后达到完全缓解的概率较低（52％对72％）。我们的数据表明，异常表达CD16和CD56的AML患者生存结局不良。